PHARMACY

FDA approves cystic fibrosis drug Orkambi

BY David Salazar

SILVER SPRING, Md. — The Food and Drug Administration recently approved Vertex Pharmaceuticals’ Orkambi (lumacaftor 200 mg/ivacaftor), a new cystic fibrosis treatment that received designation from the FDA as a breakthrough therapy and as an orphan drug.

Orkambi is specifically for individuals with cystic fibrosis with a mutation (F508del) that disrupts water and chloride transportation in the body by producing an abnormal protein. The leading cause of the disease is when an individual inherits one copy of this mutation from each parent.

“The FDA encourages manufacturers to develop new and innovative treatments for serious rare diseases like cystic fibrosis,” John Jenkins, director of the Office of New Drugs at the Center for Drug Evaluation and Research said. “Today’s approval significantly broadens the availability of targeted treatments for the specific defects that cause cystic fibrosis.”

The FDA approved Orkambi after a priority review, which is conducted in a shorter time than most reviews for drugs the agency believes can offer significant safety and efficacy improvements over currently available drugs. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Rite Aid posts 2.4% in June same-store sales to kick off summer

BY Michael Johnsen

CAMP HILL, Pa. – In the first full month of Rite Aid's new wellness+ with Plenti loyalty program, Rite Aid posted a same-store sales increase of 2.4% for the four weeks ended June 27, the company reported Thursday. June front-end same-store sales increased 0.3%. Pharmacy same-store sales, which included an approximate 226 basis points negative impact from new generic introductions, increased 3.4%. 
 
The wellness+ with Plenti program is expected to be a key customer acquisition tool moving forward. 
 
Prescription count at comparable stores increased 0.2% over the prior-year period.  
 
Total drug store sales for the four-week period increased 2.2% to $2 billion. Prescription sales accounted for 69% of drug store sales, and third party prescription sales represented 97.8% of pharmacy sales.  
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Report: PANTHERx expands specialty pharmacy business

BY Antoinette Alexander

PITTSBURGH — Specialty pharmacy PANTHERx has expanded its specialty pharmacy business and doubled its workforce, according to a local news report.

Founded in 2011, PANTHERx has expanded its pharmacological support services for organ transplant patients, the Pittsburgh Business Times reported, while adding medications for HIV, hepatitis C and skin conditions.

In less than a year, the company has also doubled its workforce to 40 full-time associates, according to the article.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?